Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
Phase 1/2UNKNOWN 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Toxicity, Drug
Conditions
Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy
Trial Timeline
Jul 31, 2018 → Nov 29, 2025
NCT ID
NCT03638375About Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha is a phase 1/2 stage product being developed by Bristol Myers Squibb for Toxicity, Drug. The current trial status is unknown. This product is registered under clinical trial identifier NCT03638375. Target conditions include Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03638375 | Phase 1/2 | UNKNOWN |
Competing Products
7 competing products in Toxicity, Drug
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TURALIO™ | Daiichi Sankyo | Pre-clinical | 23 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| Saquinavir | Roche | Phase 2 | 52 |
| Doxycycline 50Mg Tablet | Amgen | Phase 2 | 51 |
| HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100 | Amgen | Phase 1 | 32 |
| ClinOleic (Baxter Healthcare, Deerfield, IL, USA) | Baxter | Phase 1 | 30 |
| Ryanodex (dantrolene sodium) for injectable suspension | Eagle Pharmaceuticals | Phase 2 | 44 |